RxDoctor Payments Data

Stephen Dillon, MD

Internal Medicine · New York, NYNPI 1609855394

Payments from drug & device makers

$14,025in general payments, 2019–2025

Across 614 payments — averaging $22.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$3K
  • Viiv Healthcare Company$2K
  • Johnson & Johnson$961
  • AbbVie$818
  • Merck$776
  • Novo Nordisk$433
  • plus $6K from 46 others

What the payments were for

  • Food & beverage$13,89399%
  • Education$1311%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,025 in reported general payments places this provider in the 90th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$13,846
Medicare patients
92
Services billed
120

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala177$835,972
TriumeqAbacavir/Dolutegravir/Lamivudi88$348,102
TivicayDolutegravir Sodium94$270,356
DescovyEmtricitabine/Tenofov Alafenam101$244,276
DovatoDolutegravir Sodium/Lamivudine50$164,556
IsentressRaltegravir Potassium62$145,040
Etravirine46$54,824
GenvoyaElviteg/Cob/Emtri/Tenof Alafen13$47,853
JulucaDolutegravir/Rilpivirine12$46,578
Darunavir35$39,979
Emtricitabine-Tenofovir DisopEmtricitabine/Tenofovir (Tdf)44$20,514
Atazanavir Sulfate28$19,848
VascepaIcosapent Ethyl37$13,026
Ritonavir48$9,870
EliquisApixaban12$9,474

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy, Descovy, Genvoya$2,831$1,128,102291 claims
Viiv Healthcare CompanyTriumeq, Tivicay, Dovato, Juluca$2,252$829,592244 claims
MerckIsentress, Januvia$776$153,89378 claims
PfizerEliquis$307$9,47412 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →